INTENSIVE DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE FOLLOWED BY AUTOLOGOUS STEM-CELL RESCUE - RESULTS OF A PHASE-I/II STUDY IN BREAST-CANCER PATIENTS

被引：21

作者：

FIELDS, KK

PERKINS, JP

HIEMENZ, JW

ZORSKY, PE

JANSSEN, WE

KRONISH, LE

MACHAK, MC

ELFENBEIN, GJ

机构：

[1] Division of Bone Marrow Transplantation, Department of Internal Medicine, at the H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida

来源：

SURGICAL ONCOLOGY-OXFORD | 1993年 / 2卷 / 01期

关键词：

BONE MARROW TRANSPLANT; BREAST CANCER; CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; PERIPHERAL BLOOD STEM CELL TRANSPLANT;

D O I：

10.1016/0960-7404(93)90049-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We have recently treated 66 women with breast cancer with escalating doses of ifosfamide, carboplatin, and etoposide (ICE) followed by autologous stem cell rescue (ASCR). Patients received ifosfamide (6000-24,000 mg m-2), carboplatin (1200-2100 mg m-2), and etoposide (1800-3000 mg m-2) divided over 6 days with ASCR 48 h after completion of chemotherapy. Our patient population consisted of seven patients with stage II disease with eight or more positive nodes being treated in the adjuvant setting, 16 patients with a history of stage III or inflammatory breast cancer, and 43 patients with stage IV disease. Six patients were not evaluable for response due to early death from infection (three patients) and incomplete restaging (three patients). The overall response rate in patients with measurable metastatic disease was 50%. Of those patients with stage II disease, 85% remain alive and progression-free with a median follow-up of greater than one year. The two most frequent toxicities encountered were reversible elevations of liver function tests and mucositis/enteritis. The dose-limiting toxicities were central nervous system toxicity and nephrotoxicity.

引用

页码：87 / 95

页数：9

共 16 条

[1]

Antman, Corringham, de Vries, Et al., Dose intensive therapy in breast cancer, Bone marrow Transpl, 10, pp. 67-73, (1992)

[2]

Fields, Elfenbein, Saleh, Et al., Ifosfamide, carboplatin, and etoposide in combination for induction and high-dose chemotherapy: focus on breast cancer and lymphoma, Hem Onc, 10, pp. 61-74, (1992)

[3]

Peters, Shpall, Jones, Et al., High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer, J Clin Oncol, 6, pp. 1367-1376, (1988)

[4]

Antman, Ayash, Elias, Et al., A Phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy, J Clin Oncol, 10, pp. 102-110, (1992)

[5]

Hortobagyi, Frye, Buzdar, Et al., Complete remissions in metastatic breast cancer: a thirteen year follow-up report, Proc Am Soc Clin Oncol, 7, (1988)

[6]

Schaake-Koning, van der Linden, Hart, Et al., Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study, Int J Radiat Oncol Biol Phys, 11, pp. 1759-1763, (1985)

[7]

Fisher, Bauer, Wickerman, Et al., Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer, Cancer, 52, pp. 1551-1557, (1983)

[8]

Eder, Elias, Shea, Et al., A Phase I-II study of cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow transplantation in solid tumour patients, J Clin Oncol, 8, pp. 1239-1245, (1990)

[9]

Brade, Herdrich, Varini, Ifosfamide-pharmacology, safety and therapeutic potential, Cancer Treat Rev, 12, pp. 1-47, (1985)

[10]

Elias, Eder, Shea, Et al., High-dose ifosfamide with Mesna uroprotection: a Phase I study, J Clin Oncol, 8, pp. 170-178, (1990)

← 1 2 →